Cardiff Oncology doses first subject with onvansertib in Phase two ONSEMBLE trial
Codagenix names new chief strategy officer
FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial
Aadi Bioscience names new director
ONO Pharma USA's Tirabrutinib (ONO-4059) receives FDA Orphan Drug Designation
Bayer plans new clinical trial for NUBEQA in prostate cancer